🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Canada / NCT07273565
Enrolling by invitation Not applicable

Feasibility of Comparing Microwave Images to Clinical Information in Patients Recalled for Follow-up Breast Imaging

NCT07273565 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2026-03-19
Last updated
2026-06-25

Condition(s) studied

Breast - Female

Investigational drug(s) / intervention(s)

WVI-MIS-02-2025

WVI-MIS-02-2025: Microwave scans

Study summary

The goal of this clinical trial is to measure the electrical properties of breast tissues using microwave technology and to compare these collected measurements to clinical information in mammograms and/or breast ultrasound for women that have been recalled for follow-up breast imaging or further investigation. The main questions it aims to answer are:

1. Can the breast area and plate separation in the microwave scan be compared to mammogram data (where available) to assess similarity in breast positioning and the feasibility of image registration?
2. Can the distribution of electrical properties specifically glandular tissue distribution in the microwave image be compared to that observed in the mammogram (where available)?
3. Can the characteristics of the microwave image in the localized region corresponding to an identified anomaly in the breast imaging data be examined?

Study participants will be scanned with the Wave View microwave scanner on the same day as their follow-up breast imaging appointment. Each breast will be scanned up to 3 times with the scanner oriented in both the horizontal position and oriented at 45 degrees. Study participants will also be asked to fill out three surveys, one relating to breast health and the other two relating to their scanning experience.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
74 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Female sex * 18-74 years of age * Able to provide informed consent * Had a screening or diagnostic mammogram or breast ultrasound within the previous 6 weeks * Recalled for additional breast imaging due to BIRADS 3 or 4 or 5 findings. Exclusion Criteria: * Participants who have not received a mammogram or breast ultrasound * Participants who are currently undergoing breast cancer treatment or have had treatment in the past 6 months * Participants with breast implants * Participants who are pregnant or breastfeeding * Participants with active breast skin infections * Participants with nipple piercings (unless they are removed prior to scanning) * Participants with an implanted electronic device * Participants with physical limitations that prevent them from placing their breasts inside the Wave View scanner.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Pureform Radiology Calgary Canada

More University of Calgary trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07273565 on ClinicalTrials.gov ↗ ← All trials in Canada